alexa Value Of GATA-3 Expression In Diagnosis Of Metastatic Breast Carcinoma
ISSN: 2161-1076

Surgery: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

13th International Conference on Surgical Pathology & Practice
March 27-28, 2017 Madrid, Spain

Nafissa El Badawy, Faten Ghazal, Manal El Mahdy, Rola Farid and Shimaa Abd El Raouf
Ain Shams University, Egypt
ScientificTracks Abstracts: Surgery Curr Res
DOI: 10.4172/2161-1076.C1.029
Background: Triple negative breast carcinomas and about half of metastatic breast carcinomas are negative for estrogen receptor (ER), gross cystic disease fluid protein 15 (GCDFP-15), and mammaglobin (MGB) which are commonly used as breast-specific immunomarkers. However, GATA-3 has emerged recently as a sensitive and relatively specific immunomarker for breast and urothelial carcinomas, but the data documenting its expression in different molecular subtypes of breast carcinomas are limited. Also, few studies have specifically assessed the distribution of GATA-3 among different immunohistochemical and histomorphologic subtypes of breast carcinoma, specifically, its expression in “triple-negative". Aim: The purpose of this study is to evaluate the expression of GATA-3 in different molecular subtypes of breast carcinoma, particularly, in metastatic breast carcinomas. Materials & Methods: A total of 85 selected cases were included in the current study categorized into: 60 cases of primary invasive breast carcinomas divided according to immunohistochemical studies for hormonal receptors into: ER positive, HER2 positive, and triple-negative subtypes. In addition, 25 cases of metastatic adenocarcinomas were also included. Results: Overall GATA-3 expression was detected in 90% of primary breast carcinoma cases. The current study showed a highly significant statistical correlation between GATA-3 expression and the molecular subgroup of primary breast carcinomas. Positive GATA-3 expression was detected in all (luminal) ER positive cases. On the other hand, 80% of HER2 positive and 90% of triple negative subtypes showed GATA-3 expression. Moreover, 96% of the metastatic group showed positive GATA-3 labeling. Conclusions: Our data suggest that GATA-3 is a breast-specific immunomarker, especially when encountering ER-negative and metastatic breast carcinomas.

Nafissa El Badawy is a Professor of Pathology at Ain Shams University, Cairo, Egypt and President of the Scientific Council of the Egyptian Board of Pathology. She has graduated from the Faculty of Medicine from Ain Shams University, Cairo, Egypt in 1978 followed by the fellow of Emory University, Atlanta, Georgia, USA in 1990. In 1994, she was a fellow of Heinrich Hein University, Dusseldor, Germany.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version